ocular myasthenia gravis: past, present, and future
TRANSCRIPT
![Page 1: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/1.jpg)
Ocular Myasthenia Gravis: Past, Present, and Future
Victoria S. Pelak, MDDepartments of Neurology and OphthalmologyUniversity of Colorado Health Sciences Center
![Page 2: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/2.jpg)
Ocular Myasthenia Gravis
1. Definition and Natural History2. Epidemiology3. Anatomy & Pathophysiology4. Clinical features & Differential Dx5. Diagnostic tests 6. Treatment7. Future Options
![Page 3: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/3.jpg)
Definition
• Weakness and fatigability of cranial, limb, respiratory muscles– “generalized”
• Levator palpebrae superioris, EOMs, and orbicularis oculi– “ocular”
• 15% purely “ocular”
![Page 4: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/4.jpg)
Natural History
Ocular symptoms in Myasthenia Gravis:
• 50% present solely with
• 75-80% have on presentation
• 90% eventually develop
![Page 5: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/5.jpg)
Natural History (Grob et al. ’81)
• ~2/3 will generalize• Who?• When?
– first 7 months– OMG @ 1 year: 84% will NOT – OMG @ 2 years: 88%– OMG @ 3 years: 92%
![Page 6: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/6.jpg)
Historical Perspective
• Thomas Wills 1672• Samuel Wilks 1877• Ernst Sauerbrch 1912• Mary Walker 1934• C.E. Chang 1962• 1970s
Thomas Wills
![Page 7: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/7.jpg)
Epidemiology: Incidence
• Incidence MG:4-14/100,000age and gender related• generalized: early peak late peak • ocular: late peak
![Page 8: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/8.jpg)
0
20
40
60
80
100
120
140
1st 2nd 3rd 4th 5th 6th 7th 8th
womenmen
n=868
Generalized Myasthenia (Grob et al. ‘81)
![Page 9: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/9.jpg)
0
5
10
15
20
25
30
35
1st 2nd 3rd 4th 5th 6th 7th 8th
womenmen
Ocular Myasthenia (Grob et al. ‘81)
n=168
![Page 10: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/10.jpg)
Epidemiology: Mortality (Grob et el. ’87)
1915-34: 70%
1935-39: 40%
1940-57: 33%
1958-65: 14%
1966-85: 7%
1934: anticholinesterase
1939: assisted ventilation
1960: pressure or volume
1966: steroid use
![Page 11: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/11.jpg)
Epidemiology: Associated Conditions
• Thyroid dysfunction
• Rheumatoid Arthritis
• Ankylosing spondylitis
![Page 12: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/12.jpg)
Anatomy & Pathophysiology
• Anatomy– Neuromuscular junction
• Pathophysiology– Causes– Autoimmune
![Page 13: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/13.jpg)
Anatomy
• Central nervous system• Peripheral nerve• Neuromuscular junction• Muscle• Combination
![Page 14: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/14.jpg)
Neuromuscular Junction
Electrical impulse
Chemical impulse
Electrical impulse
![Page 15: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/15.jpg)
Neuromuscular Junction Disorders
• Myasthenia Gravis• Lambert Eaton-Myasthenic Syndrome (LEMS)• Toxic or Metabolic
– Botulism– Hypermagnesemia– Drugs (D-Penicillamine)– Organophosphate toxicity– Snake, spider, scorpion bites
![Page 16: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/16.jpg)
Pathophysiology: Causes
• Autoimmune
• Neonatal
• Congenital
• Drug-induced
![Page 17: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/17.jpg)
Neonatal Myasthenia Gravis
• Passive transfer of IgG
• 10 – 30% mothers with MG
• 0 – 3 d after birth
• Transient: 1-6 weeks
• Weak cry, poor suck, hypotonia
![Page 18: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/18.jpg)
Congenital Myasthenia Gravis
• Genetic defects
• Birth or infancy
• Ocular +/- generalized
• Fluctuate, stable
![Page 19: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/19.jpg)
Neonatal MG
Congenital MG
Maternal MG
(+)
(-)
Onset 0-3 days postnatal
birth - infancy
Weakness generalized
ocular +/- generalized
Time Course
remission 1-6 wks
fixed
Antibodies usually (+) no
![Page 20: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/20.jpg)
Drug-induced Myasthenia Gravis
• D-Penicillamine
![Page 21: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/21.jpg)
Autoimmune Myasthenia Gravis
1. Postsynaptic disorder
2. Decreased acetylcholine receptors
• Immune-mediated
![Page 22: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/22.jpg)
Pathophysiology
![Page 23: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/23.jpg)
Clinical Features: OMG
• Ptosis
• Diplopia
• Orbicularis oculi weakness
![Page 24: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/24.jpg)
Ptosis• Isolation or with ophthalmoplegia• Fluctuates and shifts• Usually asymmetric• Examination:
– Fatigability– “Cogan’s lid twitch”– Curtaining– Eyelid retraction
![Page 25: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/25.jpg)
Ocular Motility Deficits
• Any pattern – pseudo INO– pseudo 3rd, 4th, 6th
– pseudo cavernous sinus syndrome– Exam changes
• Medial rectus
![Page 26: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/26.jpg)
Orbicularis Oculi Weakness
• Common• Most commonly affected muscles:
1. levator palpebrae superioris2. EOMs3. orbicularis oculi4. proximal limb 5. facial expression, mastication, speech6. neck extensors
![Page 27: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/27.jpg)
Differential Diagnosis
• Ocular Myasthenia– PEO– Oculopharyngeal
dystrophy– Thyroid eye disease– Intracranial mass lesion– “Senile” ptosis
• Bulbar Dysfunction– Motor neuron syndromes– Oculopharyngeal dystrophy– Polymyositis
• Generalized Myasthenia– Lambert-Eaton syndrome– Botulism– Myopathy
![Page 28: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/28.jpg)
Diagnostic Tests
• Anti-Acetylcholine Receptor Antibodies
• Tensilon Test
• Electromyography
• Response to mestinon
• Ice test
![Page 29: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/29.jpg)
Anti-Acetylcholine Receptor Antibodies
• Present in 80-90% of generalized
• Present in 50% of ocular
• No difference in severity, response, or prognosis
![Page 30: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/30.jpg)
Tensilon Test
• OMG: + 75%
• False positive
• Onset in 30s, lasts 1- 5 minutes
• Heart disease and elderly
• Atropine available
![Page 31: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/31.jpg)
Electromyography
• Repetitive nerve stimulation– 60-90% generalized– 20-30% OMG
• Single fiber EMG– 90-100% generalized– 80-90% OMG
![Page 32: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/32.jpg)
Mestinon Response
• Poor in OMG
• Ptosis
• Motility
![Page 33: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/33.jpg)
Ice Test
• Ice pack on more ptotic lid x 2 minutes
• Ptosis– 92% in MG– 0 non MG
• Substitute for tensilon
Borenstien et al. ‘75
![Page 34: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/34.jpg)
Ice Test: Case of 75 year old woman
• Negative antiacetylcholine receptor antibodies• Negative RNS and SFEMG • Negative Tensilon test x 2• No response to mestinon
• Ice pack at home when “eye” closed shut
![Page 35: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/35.jpg)
Treatment
• Cholinesterase inhibitors (Mestinon)• Immunosuppresion:
– prednisone– cyclosporine– azathioprine (Imuran)
• Thymectomy• Acute therapies
– IVIg– Plasmapheresis
![Page 36: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/36.jpg)
Cholinesterase Inhibitors (Mestinon)
• Response often incomplete– ptosis– diplopia
• Onset 30’, half life of 3-4 hours• SE: diarrhea• Caution: cardiac conduction defects
![Page 37: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/37.jpg)
Prednisone
• OMG: good response
• Maintain high dose ~ 3 months or stable
• Lowest effective dose– once determined alternate day therapy– majority need indefinitely
• Caution: steroid-induced exacerbation
![Page 38: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/38.jpg)
Cyclosporine and Azathioprine
• Occasionally used in OMG
• Toxicity
• Indications:– resistant to steroids– need to reduce steroid dose
• >50 mg qod• significant SE
![Page 39: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/39.jpg)
Thymectomy
• Definite indications:1. Generalized: puberty – 60 years2. Thymoma (15%)
• OMG w/o thymoma: not rec
• Response: months-years
![Page 40: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/40.jpg)
Acute Therapies: IVIg and Plasmapheresis
• Short term – transient (days to weeks)
• Not indicated in OMG
• Indications in GMG
![Page 41: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/41.jpg)
Alternatives to Medical Treatment
• Ptosis– ptosis crutches– ptosis surgery: not recommended
• Diplopia– patch– prisms: too variable– strabismus surgery: poor outcome
![Page 42: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/42.jpg)
Drug PrecautionsAntibiotics: aminoglycosides, neomycin, streptomycin,
kanamycin, gentamicin, tobramycin, netilmicin, amikacin,
Other: tetracycline, ciprofloxacin, erythromycin
Anticonvulsants: dilantin
Antimalarials: chloroquine, quinine
Cardiovascular: quinidine, procainamide, verapamil, timolol, propanolol
Ophthalmic: betaxolol, timolol
Psychotropic: lithium, chlorpromazine
Rheumatologic: D-penicillamine, chloroquine
![Page 43: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/43.jpg)
Most Common Problems
• Aminoglycosides
• Beta blockers
![Page 44: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/44.jpg)
Studies in OMG
• Thyroid function tests• CT Chest• Review patient drug list
• Tuberculin skin test• Rheumatologic screen
![Page 45: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/45.jpg)
Future Options
• Vaccine
• Early immunosuppresion– injury to NMJ occurs during years 1-3
maximum weakness generalizationprednisone treated OMG
– trial: early IVIg
![Page 46: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/46.jpg)
Future Options
• Vaccine– Araga and Blalock ’94– Anti-idiotypic antibodies– Prevention of experimental autoimmune
myasthenia gravis
![Page 47: Ocular Myasthenia Gravis: Past, Present, and Future](https://reader031.vdocuments.us/reader031/viewer/2022020703/61fb44c02e268c58cd5c29a4/html5/thumbnails/47.jpg)
Future
• Early immunosuppresion
– injury to NMJ: year 1-3 maximum weakness generalizationprednisone treated OMG
– trial: early IVIg?